Icon

VENCLEXTA (nda208573)- (10MG,50MG,100MG)

VENETOCLAX ABBVIE
10MG,50MG,100MG
Yes No
2033-Sep-06 2021-Apr-11
2023-Apr-11 None
None No
VENCLEXTA is a BCL-2 inhibitor indicated: • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). • In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
0 0 0
Total Other Developers 13
Drugs with Suitability No
10MG ** ** - - -
50MG ** ** - - -
100MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.